ENFERMEDADES HEPÁTICAS
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (23)
2024
-
A prospective European trial comparing laparotomy, laparoscopy, robotic-assisted, and transanal total mesorectal excision procedures in high-risk patients with rectal cancer: the RESET trial
Annals of Surgery
-
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
Hepatology, Vol. 79, Núm. 1, pp. 135-148
-
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis
Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Risk factors for anastomotic leakage and postoperative outcomes after total and subtotal colectomy: A nationwide retrospective cohort study (RIALTCOT Study Collaborative Group)
Colorectal Disease, Vol. 25, Núm. 3, pp. 420-430
2022
-
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
Hepatology, Vol. 76, Núm. 4, pp. 1121-1134
-
Novel genes and sex differences in COVID-19 severity
Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806
2021
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
-
E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment
Cancer Research, Vol. 81, Núm. 11, pp. 2874-2887
-
Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?
Liver Cancer, Vol. 10, Núm. 6, pp. 545-560
-
Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis
Molecular Metabolism, Vol. 53
2020
-
Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: The randomised phase III VISNÚ-1 trial
ESMO Open, Vol. 5, Núm. 6
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25
2019
-
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study
Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500
-
Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma
Hepatology, Vol. 69, Núm. 2, pp. 587-603
-
Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicentre Study
Journal of Crohn's and Colitis, Vol. 13, Núm. 8, pp. 996-1002
2018
-
Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts
Hepatology Communications, Vol. 2, Núm. 7, pp. 807-820
-
MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis
Cell Death and Disease, Vol. 9, Núm. 10